Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects
Open accessThe DOI matches its OpenAlex record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
TGF-betas play diverse and complex roles in many biological processes. In tumorigenesis, they can function either as tumor suppressors or as pro-oncogenic factors, depending on the stage of the disease. We have developed transgenic mice expressing a TGF-beta antagonist of the soluble type II TGF-beta receptor:Fc fusion protein class, under the regulation of the mammary-selective MMTV-LTR promoter/enhancer. Biologically significant levels of antagonist were detectable in the serum and most tissues of this mouse line. The mice were resistant to the development of metastases at multiple organ sites when compared with wild-type controls, both in a tail vein metastasis assay using isogenic melanoma cells and in crosses with the MMTV-neu transgenic mouse model of metastatic breast cancer. Importantly, metastasis from endogenous mammary tumors was suppressed without any enhancement of primary tumorigenesis. Furthermore, aged transgenic mice did not exhibit the severe pathology characteristic of TGF-beta null mice, despite lifetime exposure to the antagonist. The data suggest that in vivo the antagonist may selectively neutralize the undesirable TGF-beta associated with metastasis, while sparing the regulatory roles of TGF-betas in normal tissues. Thus this soluble TGF-beta antagonist has potential for long-term clinical use in the prevention of metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manipulating the mouse embryo: A laboratory manual
Hogan, B. L. M., Costantini, F. D., & Lacy, E. (1986) · Cited by 4,460
Shull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., et al. (1992) · Nature · doi:10.1038/359693a0 · Cited by 2,985
TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders
Massagué, J., Blain, S. W., & Lo, R. S. (2000) · Cell · doi:10.1016/s0092-8674(00)00121-5 · Cited by 2,385
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
Kulkarni, A. B., Huh, C. G., Becker, D., Geiser, A., Lyght, M., Flanders, K. C., Roberts, A. B., Sporn, M. B., Ward, J. M., & Karlsson, S. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.770 · Cited by 1,967
Peptide Growth Factors and Their Receptors
Arai, K., Battey, J. F., Sporn, M. B., & Roberts, A. B. (1991) · Medical Entomology and Zoology · Cited by 1,225
Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., & Muller, W. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10578 · Cited by 1,193
Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1
Border, W. A., Okuda, S., Languino, L. R., Sporn, M. B., & Ruoslahti, E. (1990) · Nature · doi:10.1038/346371a0 · Cited by 988
Border, W. A., Noble, N. A., Yamamoto, T., Harper, J. R., Yamaguchi, Y., Pierschbacher, M. D., & Ruoslahti, E. (1992) · Nature · doi:10.1038/360361a0 · Cited by 974
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnold, A., & Schmidt, E. V. (1994) · Nature · doi:10.1038/369669a0 · Cited by 965
Cited by
A multigenic program mediating breast cancer metastasis to bone
Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Kakonen, S. M., Cordón-Cardo, C., Guise, T. A., & Massagué, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00132-6 · Cited by 2,597
Stromal fibroblasts in cancer initiation and progression
Bhowmick, N. A., Neilson, E. G., & Moses, H. L. (2004) · Nature · doi:10.1038/nature03096 · Cited by 2,302
Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer
Siegel, P. M., & Massagué, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1208 · Cited by 1,604
Targeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466
TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia
Bhowmick, N. A., Chytil, A., Plieth, D., Gorska, A. E., Dumont, N., Shappell, S., Washington, M. K., Neilson, E. G., & Moses, H. L. (2004) · Science · doi:10.1126/science.1090922 · Cited by 1,401
Steeg, P. S. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.25 · Cited by 1,363
TGFβ: the molecular Jekyll and Hyde of cancer
Bierie, B., & Moses, H. L. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1926 · Cited by 1,267
Targeting TGF-β Signaling in Cancer
Colak, S., & ten Dijke, P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.008 · Cited by 1,003
Role of tissue stroma in cancer cell invasion
De Wever, O., & Mareel, M. (2003) · The Journal of Pathology · doi:10.1002/path.1398 · Cited by 1,042
New signals from the invasive front
Christofori, G. (2006) · Nature · doi:10.1038/nature04872 · Cited by 993
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944
The polarization of immune cells in the tumour environment by TGFβ
Flavell, R. A., Sanjabi, S., Wrzesinski, S. H., & Licona-Limón, P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2808 · Cited by 940
Padua, D., & Massagué, J. (2009) · Cell Research · doi:10.1038/cr.2008.316 · Cited by 809
The two faces of transforming growth factor β in carcinogenesis
Roberts, A. B., & Wakefield, L. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1633291100 · Cited by 747
Self-citationGressner, A. M., & Weiskirchen, R. (2006) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2006.tb00292.x · Cited by 718
“In line, other investigations demonstrated that the lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis revealing that the role of TGFβ, particularly TGF-β1, in tumorigenesis, invasion, and metastasis upon environmental challenge is complex [94].”
Role of Transforming Growth Factor Beta in Human Cancer
Elliott, R. L., & Blobe, G. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.047 · Cited by 709
Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis
Grünert, S., Jechlinger, M., & Beug, H. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1175 · Cited by 678
Loeffler, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26532 · Cited by 633
Smad3 as a mediator of the fibrotic response
Flanders, K. C. (2004) · International Journal of Experimental Pathology · doi:10.1111/j.0959-9673.2004.00377.x · Cited by 608
Lahn, M., Herbertz, S., Sawyer, J. S., Stauber, A. J., Gueorguieva, I., Driscoll, K. E., Estrem, S. T., Cleverly, A. L., Desaiah, D., Guba, S. C., et al. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s86621 · Cited by 554
Development of TGF-β signalling inhibitors for cancer therapy
Yingling, J. M., Blanchard, K. L., & Sawyer, J. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1580 · Cited by 549
Terabe, M., Matsui, S., Park, J.-M., Mamura, M., Noben-Trauth, N., Donaldson, D. D., Chen, W., Wahl, S. M., Ledbetter, S., Pratt, B., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022227 · Cited by 539
Self-citationActions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer
Pardali, K., & Moustakas, A. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.06.004 · Cited by 526
Transforming growth factor-β in cancer and metastasis
Jakowlew, S. B. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9006-2 · Cited by 517
Regulation of EMT by TGFβ in cancer
Heldin, C.-H., Vanlandewijck, M., & Moustakas, A. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.02.037 · Cited by 505
Kopp, H.-G., Placke, T., & Salih, H. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2123 · Cited by 469
Schiller, M., Javelaud, D., & Mauviel, A. (2004) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2003.12.006 · Cited by 468
Transforming Growth Factor-β and the Immune Response: Implications for Anticancer Therapy
Wrzesinski, S. H., Wan, Y. Y., & Flavell, R. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1157 · Cited by 452
Siegel, P. M., Shu, W., Cardiff, R. D., Muller, W. J., & Massagué, J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932636100 · Cited by 429
Prud'homme, G. J. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700669 · Cited by 419
Uhl, M., Aulwurm, S., Wischhusen, J., Weiler, M., Ma, J. Y., Almirez, R., Mangadu, R., Liu, Y.-W., Platten, M., Herrlinger, U., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1013 · Cited by 414
NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 412
TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression
Tang, B., Vu, M., Booker, T., Santner, S. J., Miller, F. R., Anver, M. R., & Wakefield, L. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318899 · Cited by 393
Self-citationThe dynamic roles of TGF‐β in cancer
Meulmeester, E., & ten Dijke, P. (2011) · The Journal of Pathology · doi:10.1002/path.2785 · Cited by 388
Autocrine PDGFR signaling promotes mammary cancer metastasis
Jechlinger, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24652 · Cited by 371
IL-13 Activates a Mechanism of Tissue Fibrosis That Is Completely TGF-β Independent
Kaviratne, M., Hesse, M., Leusink, M., Cheever, A. W., Davies, S. J., McKerrow, J. H., Wakefield, L. M., Letterio, J. J., & Wynn, T. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.4020 · Cited by 370
Self-citationROBERTS, A., TIAN, F., BYFIELD, S., STUELTEN, C., OOSHIMA, A., SAIKA, S., & FLANDERS, K. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.008 · Cited by 348
The Dual Role of TGFβ in Human Cancer: From Tumor Suppression to Cancer Metastasis
Neel, J.-C., Humbert, L., & Lebrun, J.-J. (2012) · ISRN Molecular Biology · doi:10.5402/2012/381428 · Cited by 345
Complexities of TGF-β Targeted Cancer Therapy
Connolly, E. C., Freimuth, J., & Akhurst, R. J. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4564 · Cited by 345
TGF-β in Renal Injury and Disease
Böttinger, E. P. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.02.009 · Cited by 339
Transforming growth factor beta (TGF-β) and inflammation in cancer
Bierie, B., & Moses, H. L. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.008 · Cited by 334
Mouse models of breast cancer metastasis
Fantozzi, A., & Christofori, G. (2006) · Breast Cancer Research · doi:10.1186/bcr1530 · Cited by 331
Marino, N., Woditschka, S., Reed, L. T., Nakayama, J., Mayer, M., Wetzel, M., & Steeg, P. S. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.06.012 · Cited by 309
Transforming growth factor β as a therapeutic target in systemic sclerosis
Varga, J., & Pasche, B. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.26 · Cited by 295
Expression profiling of epithelial plasticity in tumor progression
Jechlinger, M., Grunert, S., Tamir, I. H., Janda, E., Lüdemann, S., Waerner, T., Seither, P., Weith, A., Beug, H., & Kraut, N. (2003) · Oncogene · doi:10.1038/sj.onc.1206887 · Cited by 294
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy
Tian, Y., Xie, D., & Yang, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00951-x · Cited by 293
TGF‐β as a driver of fibrosis: physiological roles and therapeutic opportunities
Budi, E. H., Schaub, J. R., Decaris, M., Turner, S., & Derynck, R. (2021) · The Journal of Pathology · doi:10.1002/path.5680 · Cited by 292
Halder, S. K., Beauchamp, R. D., & Datta, P. K. (2005) · Neoplasia · doi:10.1593/neo.04640 · Cited by 288
Puthawala, K., Hadjiangelis, N., Jacoby, S. C., Bayongan, E., Zhao, Z., Yang, Z., Devitt, M. L., Horan, G. S., Weinreb, P. H., Lukashev, M. E., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-806oc · Cited by 272
Therapeutic strategies against TGF‐β signaling pathway in hepatic fibrosis
Liu, X., Hu, H., & Yin, J. Q. (2006) · Liver International · doi:10.1111/j.1478-3231.2005.01192.x · Cited by 261
TGF-β signaling in cancer metastasis
Xie, F., Ling, L., Van Dam, H., Zhou, F., & Zhang, L. (2018) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx123 · Cited by 231
Targeting TGF-β signaling in cancer
Katz, L. H., Li, Y., Chen, J.-S., Muñoz, N. M., Majumdar, A., Chen, J., & Mishra, L. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.782287 · Cited by 212
“Expression of soluble TbRII reduced breast cancer and pancreatic cancer metastasis [143-145], and soluble TbRIII inhibited pulmonary metastasis when administered intraperitoneally to athymic nude mice [146].”
Dunn, L. K., Mohammad, K. S., Fournier, P. G. J., McKenna, C. R., Davis, H. W., Niewolna, M., Peng, X. H., Chirgwin, J. M., & Guise, T. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006896 · Cited by 212
The role of endothelial-mesenchymal transition in development and pathological process
Lin, F., Wang, N., & Zhang, T. (2012) · IUBMB Life · doi:10.1002/iub.1059 · Cited by 177
“Indeed, studies involving systemic inhibition of TGF-b signaling in adult animals have demonstrated no adverse effects and decreased metastases from mammary carcinomas (47, 48).”
BackgroundKoopman Van Aarsen, L. A., Leone, D. R., Ho, S., Dolinski, B. M., McCoon, P. E., LePage, D. J., Kelly, R., Heaney, G., Rayhorn, P., Reid, C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2307 · Cited by 146
Subramanian, G., Schwarz, R. E., Higgins, L., McEnroe, G., Chakravarty, S., Dugar, S., & Reiss, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0018 · Cited by 138
Suzuki, E., Kim, S., Cheung, H.-K., Corbley, M. J., Zhang, X., Sun, L., Shan, F., Singh, J., Lee, W.-C., Albelda, S. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2389 · Cited by 113
Connolly, E. C., Saunier, E. F., Quigley, D., Luu, M. T., De Sapio, A., Hann, B., Yingling, J. M., & Akhurst, R. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2941 · Cited by 82
Targeting key steps in metastatic tumour progression
Eccles, S. A. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.001 · Cited by 73
TGF-β/Smad Signalling in Neurogenesis: Implications for Neuropsychiatric Diseases
Hiew, L.-F., Poon, C.-H., You, H.-Z., & Lim, L.-W. (2021) · Cells · doi:10.3390/cells10061382 · Cited by 71
Suzuki, E., Kapoor, V., Cheung, H.-K., Ling, L. E., DeLong, P. A., Kaiser, L. R., & Albelda, S. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0611 · Cited by 65
Targeting the stromal microenvironment in chronic inflammation
FILER, A., PITZALIS, C., & BUCKLEY, C. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.03.007 · Cited by 45
Kim, S. K., Barron, L., Hinck, C. S., Petrunak, E. M., Cano, K. E., Thangirala, A., Iskra, B., Brothers, M., Vonberg, M., Leal, B., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.768754 · Cited by 43
COHN, A., LAHN, M. M., WILLIAMS, K. E., CLEVERLY, A. L., PITOU, C., KADAM, S. K., FARMEN, M. W., DESAIAH, D., RAJU, R., CONKLING, P., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2679 · Cited by 43
“Secondary objectives were to assess TβM1 systemic exposure and explore pharmacodynamic (PD) markers in whole blood by measuring global and specific changes in the expression of genes known to be associated with TGF-β pathway activation (29,31).”
BackgroundYang, Y., Yang, H. H., Tang, B., Wu, A. M. L., Flanders, K. C., Moshkovich, N., Weinberg, D. S., Welsh, M. A., Weng, J., Ochoa, H. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2370 · Cited by 29
“Given this complex dual role, there was initially reluctance to target the TGFb pathway in cancer, until preclinical studies in the early 2000s suggested that it might be possible to target the prooncogenic TGFb in advanced disease without disrupting effects on normal homeostasis and tumor suppression (12, 13).”
BackgroundSelf-citation
Metadata
- Authors
- Yang, Y.-A., Dukhanina, O. I., Tang, B., Mamura, M., Letterio, J. J., MacGregor, J., Patel, S. C., Khozin, S., Liu, Z.-Y., Green, J. D., Anver, M. R., Merlino, G. T., & Wakefield, L. M.
- Venue
- Journal of Clinical Investigation
- Publisher
- American Society for Clinical Investigation
- Published
- 2002-06-15
- Volume
- 109
- Issue
- 12
- Pages
- 1607-1615
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2118916648
- Cited by
- 404
- References
- 49
- FWCI
- 11.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.